secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001654954-24-014334
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets
--------------------------------------------------------------------------------

- Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.
- Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.
- Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.
- Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.
- DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/0001654954-24-014334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer